Early Phase Development

Identifying KPIs, benchmarks, key data points, and an actionable plan are all keys to accelerating study start-up cycles.

Though artificial intelligence has yet to achieve its full potential, meaningful strides are still being made across the drug discovery funnel.

Webinar Date/Time: Wednesday, November 15th, 2023 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Webinar Date/Time: Tue, Nov 14, 2023 11:00 AM EST

Webinar Date/Time: Tue, Tue, Nov 28, 2023 11:00 AM EST

The addition of NEXT Oncology investigators expands Proxima CRO’s Phase I clinical trials network.

Webinar Date/Time: Wed, May 10, 2023 11:00 AM EDT

Webinar Date/Time: Thu, Mar 2, 2023 1:00 PM EST

The struggle to translate promising movements in R&D.

Best practices for assessing publications.

How the digital environment can transform drug development space.

Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.

Rik de Greef, senior vice president of global quantitative science services at Certara discusses the organization's training initiatives in Africa.

Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.

Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.

Radiomics can help life sciences companies realize the full value of their imaging pipelines.

Pharmaceutical industry trends will directly impact the clinical diagnostic world, resulting in a more integrated therapeutic strategy.

The rapid emergence and global acceptance of new regulatory guidance has thrust cardiac safety to the forefront of new drug development during recent years. This is because the cardiac safety effects of new drugs is the most common cause of drug withdrawal from the market, or delays and a lack of regulatory approval for marketing. The resulting ECG Global Regulatory Imperative creates issues and offers opportunities for new drug developers striving for Best Practices in this important area.